Clostridium Difficile colitis- more virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs.

Slides:



Advertisements
Similar presentations
NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS
Advertisements

Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Relapsing and Severe C. difficile Disease Role of Fecal Microbiota Transfer.
Antibiotic Stewardship Curriculum Developed by: Vera P. Luther, M.D.
HIGH VALUE CARE GI CONDITIONS CHRONIC DIARRHEA EDWARD LEVINE MD OSUWMC OCTOBER 11, 2014.
Clostridium difficile Presented by Nate Smith, MD, MPH Carole Yeung, RN CIC.
Clostridium Difficile (C.diff): Fast Facts. What is Clostridium difficile (C. diff)? C. diff is a bacteria that lives in the intestinal tract of about.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Deadly Diarrhea …and the salvation of stool Teri Brentnall, M.D. Professor, Medicine Gastroenterology.
C. Difficile and Fecal Microbiota Therapy
2013 CLOSTRIDIUM DIFFICILE EDUCATIONAL AND CONSENSUS CONFERENCE March 11-12, 2013.
Clostridial infections *C.difficile is found as a part the normal bowel flora in 3-5% of the pooulation and even more commonly in hospitalized patients.
Management of Clostridium difficile Infections
Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.
MICR 420 Emerging and Re-Emerging Infectious Diseases Lecture 4: C. difficile Dr. Nancy McQueen & Dr. Edith Porter.
Monday AM report
Leav, B. A., et al.(2010) “Serum Anti-toxin B Antibody Correlates with Protection from Recurrent Clostridium Difficile Infection (CDI)”. Vaccine 28:
MRSA and VRE. MRSA  1974 – MRSA accounted for only 2% of total staph infections  1995 – MRSA accounted for 22% of total staph infections  2004 – MRSA.
C-1 Staphylococcus aureus Bacteremia and Endocarditis: A Bad Bug and A New Drug G. Ralph Corey M.D. Professor of Internal Medicine and Infectious Diseases.
MRSA and VRE. MRSA  1974 – MRSA accounted for only ____of total staph infections  1995 – MRSA accounted for _____ of total staph infections  2004 –
Antibiotic overuse and misuse in long term care Shira Doron, MD Assistant Professor of Medicine Division of Geographic Medicine and Infectious Diseases.
Big Bad Bugs in the Dialysis Unit Douglas Shemin, MD Kidney Diseases and Hypertension Division, Rhode Island Hospital.
Clostridium difficile Prevention and Treatment Katrina Beining & Christina Gardner Introduction Clostridium difficile (C. diff) is a gram-positive, spore-forming.
MRSA and VRE in a Rural Community Hospital Graduation Project 2008 Mehvish Ally.
Ellen Jo Baron, Ph.D., D(ABMM) Director of Medical Affairs, Cepheid Professor Emerita, Pathology, Stanford University Minimal TAT, Maximum Impact on Infection.
NOSOCOMIAL INFECTIONS Phase 1: Testing the efficacy of Nano-Mg (OH) 2 Dorothea A. Dillman PhD, RN, CCRN, LNC.
Top 5 Papers in Infectious Diseases Pharmacotherapy: A Review of 2013 for the General Practitioner Sharanie V. Sims, Pharm.D., BCPS (AQ-ID) Infectious.
The Human Microbiome Brian Koll, MD, FACP, FIDSA Professor of Medicine
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 83 Basic Principles of Antimicrobial Therapy.
Shira Doron, MD Assistant Professor of Medicine
SPM 100 Clinical Skills Lab 1 Standard Precautions Sterile Technique Daryl P. Lofaso, M.Ed, RRT.
Outline C. difficile infection Fecal microbiota
Confirmed cases: Deaths:. Villain NOT superhero…..
October 2, 2014 For the Georgia Hospital Association(GHA)/
Preventing and Treating C.difficile Lisa Casey, M.D. Assistant Professor, UT Southwestern Medical Center TSGE / SGNA Annual Scientific Meeting September.
SPM 100 Skills Lab 1 Standard Precautions Sterile Technique Daryl P. Lofaso, M.Ed, RRT Clinical Skills Lab Coordinator.
Clostridium difficile
Frequency of Clostridium difficile infection (CDI) transmission via ward contact with a known case Retrospective, observational study (22 months; 1 laboratory.
Lec. No. 11 Dr. Manahil Clostridium difficile C. difficile is a gram positive, spore forming, obligate anaerobe. Colonies of the organism are about 4mm.
Clostridium Difficile Infection:
R1 김동연 /prof. 이창균. Introduction  Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high.
Clostridium difficile infections
Clostridium difficile infection (CDI) 소화기내과 R4 신아리 1.
Antimicrobial Stewardship 2.0 Hospitalist Best Practice Eileen Barrett, MD, MPH, FACP Division of Hospital Medicine UNMH.
Don’t Let Your Sinus Infection Turn Into a Life Threatening Colon Infection.
© 2013 Pearson Education, Inc. Bell Ringer  What is an endospore, and what special characteristics do endospore forming bacteria have?
JAMA Internal Medicine May 2015 Volume 175, Number5 R1 조한샘 / Prof. 이창균.
Point of Care Diagnostics for Hospital Acquired Infections (HAIs): Health Economics Perspective Detection & Identification of Infectious Agents (DIIA)
Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Med Center.
Assessment of Risk-Factors for Development of Clostridium Difficile Infection in Post-Surgical Patients SCOTT BATTLE UIC SCHOOL OF PUBLIC HEALTH.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Use of Pattern Analysis to Predict Differential Relapse.
Clostridium difficile Infection Fellow 이시내. Clostridium difficile  An anaerobic gram-positive, spore-forming, toxin-producing bacillus.  Transmitted.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Clostridium difficile infection (CDI) in the ICU and Clostridium difficile outcomes in the PROSPECT Main Trial Erick Duan MD FRCPC Presented at the CCCTG.
Nosocomial Antibiotic Resistant Organisms
Clostridium difficile Infection Biology & Public Health Impact
Clostridium difficle Isolation precautions
NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS
C. difficile Detection and the Importance of Proper Specimen Collection and Testing [Name] [Title]
Improvement of management and reduction in mortality following implementation of audit recommendations in Clostridium difficile diarrhoea at James Cook.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Infection Control in ANesthesia
Oral Vancomycin as a Therapeutic Option for PSC
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Management of Clostridium Difficile Infection
Nevada ECHO ASP Clinic Quiz-What do you know about cystitis
Clostridium difficile Update
Recognising sepsis and taking action
C. difficile Update Kim Vermedal, RN, MSN, CIC APIC January 25, 2019.
Current Threats to Public Health
Presentation transcript:

Clostridium Difficile colitis- more virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital

Growing problem of pseudomembranous colitis MMWR- “…incidence, deaths, and excess health care costs are at historic highs” +/- 1 billion dollars/yr 3x increase in decade- now 500,000 infections and 29,000 deaths per year. More deaths than even MRSA infections. #1 cause of increase- over use of antibiotics #2 cause – appearance of a more virulent C.diff strain associated with risk of greater mortality #3 cause- increased relapse rate – 20% of cases have at least one relapse- difficult to treat #4 cause- overdiagnosis???

Asymptomatic C. diff Carriers 60% of stool carriers in one study also had it on their skin and their surrounding environment Spores on the skin of these carriers were easily transferred to others Non-poopers are important sources of potential infection to others- everyone should wash with soap and water!

Hospitals started seeing very severe cases of C.diff colitis with high mortality

The C. difficile had now become resistant to common antibiotics and flourished in the hospital

NAP-1 C. diff strain- nasty super bug now seen throughout Nevada and USA. Approx. 1/2 of all cases in NV are NAP-1 positive!!! resistant to common antibiotics overused in hospital, particularly fluoroquinolones A genetic mutation allows 10 to 20x more toxin A and B to be secreted, plus it has its own unique binary toxin More likely to progress to fulminant disease and death Increased rate of spore germination to active disease increases likelihood of relapse If your micro lab does a PCR test, they are already testing for NAP-1, but you may need to request results

C. Diff Lab Diagnosis Direct culture- not used - $$$/slow turn around time ELISA- Is the C. diff producing toxin? – detect toxin A +/- toxin B. Detects the toxin, but misses some cases – about 70% sensitive. Is that important? C. diff PCR- positive test tells you C. difficile carrying the toxin gene is present in the stool. 100% sensitive, but DOES NOT differentiate between asymptomatic carriers and toxin producers. Do not order as a test of cure!

Date of download: 2/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era JAMA Intern Med. 2015;175(11): doi: /jamainternmed Kaplan-Meier Curves of Time to Resolution of Diarrhea by Clostridium difficile Test GroupThe median duration of diarrhea for patients with at least 1 day was 3 days (interquartile range, 1-6 days) for Tox+/PCR+ (121 of 131), 2 days (interquartile range, 1-4 days) for Tox−/PCR+, and 2 days (interquartile range, 1-3 days) for Tox−/PCR− (927 of 1123) (P <.001). Log-rank P values are P <.001 for all groups, P =.003 for Tox+/PCR+ vs Tox−/PCR+, (143 of 162) P <.001 for Tox+/PCR+ vs Tox−/PCR−, and P <.001 for Tox−/PCR+ vs Tox−/PCR−. Tox+/PCR+ indicates C difficile toxin immunoassay positive and polymerase chain reaction positive; Tox−/PCR+, C difficile toxin immunoassay negative and polymerase chain reaction positive; Tox−/PCR−, C difficile toxin immunoassay negative and polymerase chain reaction negative. Figure Legend:

Are we over-diagnosing C. diff infection? Careful patient selection is vital Up to 50% of tested patients don’t have significant diarrhea Up to 40% are on a laxative regimen when tested The PCR test may be 100% sensitive, but only a 45% positive predictive value for CDI There is no difference in length of diarrhea or mortality in toxin-/PCR+ or toxin -/pcr- patients !

Negative consequences of over-treating CDI Contact precautions adversely effect the patient- anxiety, depression, isolation Receive unnecessary antibiotics that can paradoxically increase risk of actual CDI and select for VRE etc Expense of isolation, need for single room Adversely effect hospital infection incidence rate

Human beings as ecosystems- not just an individual, but a collaborative effort between commensal bacteria and their host

Original Article Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile Els van Nood, M.D., Anne Vrieze, M.D., Max Nieuwdorp, M.D., Ph.D., Susana Fuentes, Ph.D., Erwin G. Zoetendal, Ph.D., Willem M. de Vos, Ph.D., Caroline E. Visser, M.D., Ph.D., Ed J. Kuijper, M.D., Ph.D., Joep F.W.M. Bartelsman, M.D., Jan G.P. Tijssen, Ph.D., Peter Speelman, M.D., Ph.D., Marcel G.W. Dijkgraaf, Ph.D., and Josbert J. Keller, M.D., Ph.D. N Engl J Med Volume 368(5): January 31, 2013

Rates of Cure without Relapse for Recurrent Clostridium difficile Infection. van Nood E et al. N Engl J Med 2013;368:

Some new C. diff Developments The Beagle “Sniff” test as a near perfect diagnostic test Tigecycline looks to be an effective antibiotic in fulminant C.diff combined with oral vanco and iv metronidazole Enthusiasm for stool transplant, now available in (Jelly Belly Diarrhea Flavored ?) gelatin capsules!

New surgical approach for fulminant colitis- less invasive, better mortality Traditional – total colectomy Double-barrel ileostomy – preserves colon, much lower mortality

Test time!

I. Which fact is incorrect about C. diff? Causes 500,000 cases per year Severity of illness has increased last few years Majority of C. diff cases are community acquired Relapses are major problem with C. diff and may respond to stool transplant

II. Which of the following is incorrect regarding medical management of C. diff? Oral metronidazole is recommended for mild C. diff Oral vancomycin is preferred for moderate or severe C.diff Patients with fulminant C. diff with ileus should receive intravenous vancomycin

III. Manifestations of fulminant C. diff include all the following except: Severe abd pain and worsening diarrhea Hypotension requiring vasopressors Dropping WBCs Respiratory failure requiring intubation Elevated lactate levels Renal failure

IV. Increased virulence of NAP-1 strain is a result of which of the following ? Lower rates of germination Higher resistance to anti-fungal agents Gene mutation leading to reduced toxin production Ability to produce large amounts of toxin A and B that overwhelm treatment attempts

V. New approaches to C. diff infection include all of the following except: PCR testing for quicker and more sensitive diagnosis – but may result in over-treatment of a carrier state Stool transplant for recurrent disease Less invasive surgical techniques to improve outcome and allow for earlier intervention Fidaxomicin as an inexpensive and effective oral therapy for NAP-1 strain infections